Emergent BioSolutions Inc reports results for the quarter ended June 30 - Earnings Summary

• Emergent BioSolutions Inc EBS.N reported quarterly adjusted earnings of 16 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-2.32. The mean expectation of three analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -72 cents to -26 cents per share.

• Revenue fell 44.7% to $140.90 million from a year ago; analysts expected $146.37 million.

• Emergent BioSolutions Inc's reported EPS for the quarter was a loss of 22 cents​.

• The company reported a quarterly loss of $12 million.

• Emergent BioSolutions Inc shares had fallen by 4.4% this quarter and lost 36.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 215.3% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 55.3% above its last closing price of $6.03

This summary was machine generated from LSEG data August 6 at 10:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)